AVTX-802
PMM2-CDG (Congenital Disorder of Glycosylation)
Phase 2Active
Key Facts
Indication
PMM2-CDG (Congenital Disorder of Glycosylation)
Phase
Phase 2
Status
Active
Company
About Avalo Therapeutics
Avalo Therapeutics is a U.S.-based, clinical-stage biotechnology company with a mission to develop and commercialize targeted therapeutics for significant unmet needs in immunology and immuno-oncology. Its core strategy involves advancing a pipeline of immune-modulating assets through clinical development, aiming for proof-of-concept data and strategic partnerships. The company operates as a public entity, navigating the high-risk, high-reward landscape of drug development, with its valuation heavily influenced by clinical trial catalysts and financing events.
View full company profile